Pulmotype is a five antibody immunohistochemistry (IHC) test developed by Applied Genomics that can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer (NSCLC) tumor specimens. The histologic classification of non-small cell lung tumors has gained clinical relevance because newly developed targeted therapies show different clinical effectiveness or toxicity dependent upon the histotype of the tumor. There is currently no widely accepted molecular-based tool to help distinguish the different histological types.

Pulmotype was developed with a 551 patient surgical specimen lung carcinoma retrospective cohort from a regional hospital and validated on three independent cohorts comprised in total of over a thousand cases. Pulmotype can play an immediate role to pathologists in complimenting the morphological assessment of lung carcinoma histological types resulting in an accurate histotype diagnosis and more informed therapy decisions.